KYORIN Pharmaceutical Co., Ltd.

PickUp

These websites are only available in Japanese.

News Releases

November 19, 2025: World's First Mitochondrial Disease Treatment 'MA-5' Commences Phase II Clinical Trial
November 7, 2025: Consolidated Financial Results for the Six Months Ended September 30, 2025) [Japanese GAAP]
November 7, 2025: Consolidated Financial Results for Second Quarter (Interim Period) of FY2025 - Supplementary Information
October 16, 2025: Announcement of Presentation in Academic Conference Regarding Result of Specified Clinical Trial using Digital Therapeutics for Tinnitus
October 1, 2025: KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases

About Kyorin

KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.

More detail

Investor Relations

This section provides information on the long-term vision, medium-term business plan, financial and performance results, IR library and stock.

More detail

Sustainability

Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.

More detail

R&D

A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

More detail

PickUp

News Releases

Contens

About Kyorin

Investor Relations

Sustainability

R&D

Kyorin Group